PMPerizat Mukhamedzhanova

Perizat Mukhamedzhanova

*This is an algorithmically generated author record based on publicly available information.

Perizat Mukhamedzhanova has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prospects for Treatment of Lung Cancer Using Activated Lymphocytes Combined with Other Anti-Cancer Modalities

    by Anastasia Ganina, Manarbek Askarov, Larissa Kozina, Madina Karimova, Yerzhan Shayakhmetov, Perizat Mukhamedzhanova, Aigul Brimova, Daulet Berikbol, Elmira Chuvakova, Lina Zaripova, et al.

    This review explores the significance and prospects of using diverse T-cell variants in the context of combined therapy for lung cancer treatment. Recently, there has been an increase in research focused on understanding the critical role of tumor-specific T lymphocytes and the potential benefits of autologous T-cell-based treatments for individuals with lung cancer. One promising approach involves intravenous administration of ex vivo-activated autologous lymphocytes to improve the immune status of patients with cancer. Investigations are also exploring the factors that influence the success of T-cell therapy and the methods used to stimulate them. Achieving a comprehensive understanding of the characteristics of activated lymphocytes and deciphering the mechanisms underlying their activation of innate anti-tumor immunity will pave the way for numerous clinical trials and the development of innovative strategies for cancer therapy like combined immunotherapy and radiation therapy.


  • Open Access

    Prospects for Combined Treatment of Non-Small Cell Lung Cancer Using Autologous Activated Lymphocytes

    by Anastasia Ganina, Manarbek Askarov, Larissa Kozina, Madina Karimova, Yerzhan Shayakhmetov, Perizat Mukhamedzhanova, Aigul Brimova, Daulet Berikbol, Elmira Chuvakova, Lina Zaripova, et al.

    This review article explores the significance and prospects of using diverse T-cell variants in the context of combined therapy for lung cancer treatment. Recently, there has been an increase in research focused on understanding the critical role of tumor-specific T-lymphocytes and the potential benefits of autologous T-cell-based treatments for individuals with lung cancer. One promising approach involves intravenous administration of ex vivo-activated autologous lymphocytes to improve the immune status of patients with cancer. Investigations are also exploring the factors that influence the success of T-cell therapy and the methods used to stimulate them. Achieving a comprehensive understanding of the characteristics of activated lymphocytes and deciphering the mechanisms underlying their activation of innate anti-tumor immunity will pave the way for numerous clinical trials and the development of innovative strategies for cancer therapy.